期刊
PROSTATE
卷 63, 期 3, 页码 252-258出版社
WILEY
DOI: 10.1002/pros.20181
关键词
prostate cancer; antibodies; autoantibodies; tumor-associated antigen; p62; p90
资金
- NCI NIH HHS [CA56956, R01 CA059979, R01 CA056956, CA59979] Funding Source: Medline
- NCRR NIH HHS [M01 RR00833, M01 RR000833, RR08124] Funding Source: Medline
BACKGROUND. Cytoplasmic p90 autoantigen was recently cloned from a cDNA expression library using serum antibody from a cancer patient. The humoral immune response to p90 in prostate cancer and benign prostatic hyperplasia (BPH) was examined. METHODS. An antigenic fragment of recombinant p90 protein and several other tumor-associated antigens (TAAs) were used in ELISA and Western blotting to detect antibodies in sera from patients with prostate cancer, BPH, and other controls. METHODS. An antigenic fragment of recombinant p90 protein and several other tumor-associated antigens (TAAs) were used in ELISA and Western blotting to detect antibodies in sera from patients with prostate cancer, BPH, and other controls. RESULTS. Autoantibodies to p90 were detected in 30.8% of 133 prostate cancer patients versus 1.5% in 68 BPH patients. When a selected panel of six TAAs including p90 were used for immunoscreening, the cumulative positive reactions in prostate cancer sera reached 92.5%, significantly higher than in BPH and other control sera. Antibodies to p90 showed the highest frequency in prostate cancer (30.8%), followed by antibodies to p62 (22.6%). CONCLUSIONS. A panel of six selected TAAs was shown to have high sensitivity and specificity as immunodiagnostic markers in prostate cancer. (c) 2004 Wiley-Liss. Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据